• ValiRx forms advisory board Dr Satu Vainikka, Chief Executive Officer of ValiRx

    ValiRx’s has formed an Advisory Board to support its main board in new strategic guidance and technical advice.

  • Herantis announces initial plans for continued development of Lymfactin

    Herantis Pharma’s clinical study with its investigational gene therapy product Lymfactin for treating secondary lymphedema has advanced to the last patient cohort, owing to good reported safety, the company said Thursday.

  • Shield Therapeutics: Ferric maltol may be effective in patients with active inflammatory markers Shield Therapeutics logo

    Shield Therapeutics’s study suggests that ferric maltol may be effective in patients with active inflammatory markers, and that the ongoing comparative trial of ferric maltol against iv iron will be useful to challenge the prevalent doctrine prohibiting treatment of patients with active systemic inflammation with oral iron.

  • Briefing on some biotech stocks

    In a daily briefing, Daily Stock Tracker (DST) gave some insight on certain biotech stocks, noting that companies in this space are almost always unprofitable, and many have no real revenue at all.

  • Drugmaker Mylan gets boost from unlikely source: coal FILE PHOTO - EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. on August 24, 2016. REUTERS/Jim Bourg/File Photo

    Mylan N.V. <MYL.O> is best known for producing EpiPen emergency allergy treatments and generic drugs.

  • U.S. Supreme Court ruling threatens masive talc litigation against J&J FILE PHOTO: Bottles of Johnson & Johnson baby powder line a drugstore shelf in New York October 15, 2015. REUTERS/Lucas Jackson/File Photo

    Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

  • Breast cancer patients testing Enzychem’s cheaper Mosedipimod, hopes for FDA’s approval

    Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.

  • Enable Injections presents syringe transfer system in a conference

    Enable Injections debuts the first multi-vial/multi syringe system for biologics delivery. The small, handheld device can also be used for variable dosing based on patient’s weight, providing maximum flexibility and ease of use with a minimum of waste.

  • Sanovas expands in China, $75 million in capitalization

    Sanovas, Inc., a Life Science technology company will establish a venture capital fund and Innovation Center at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences to advance the company’s innovations and sales in China.

  • Texas becoming big player in life science and biotech industry

    Texas is headed to San Diego this week to showcase the state’s thriving biotechnology and life sciences sector at the world’s largest biotechnology conference, BIO International. More than 16,000 biotechnology and pharmaceutical leaders are expected to attend the annual conference, said Texas Economic Development Corporation.

  • World Molecular biology 2017 conference

    Molecular Biology 2017 aims to shed focus on the transnational nature of biotechnological research, with emphasis on both the
    basic science as well as its applications in industry and academia. Latest researches, agricultural Molecular Biology, business models,
    pharmaceutical Molecular Biology, medical Molecular Biology, cancer biology, immunology, genetics, protein engineering,
    plant and environmental technologies, transgenic plant and crops, bio remediation, and microbial diversity research will be the subjects of discussion.

  • 100 Healthy Years – Are Kids Prepared?

    Merck, one of the worlds most renown science and technology companies, summoned experts from worlds organizations such as UN, UNICEF, UNAIDS, World Obesity Federation and McKinsey at the the company’s headquarters in Darmstadt, Germany, to discuss questions about the most urgent threats to our children’s long-term health, or what can be done both inside and outside the classroom? And how do schools, parents and communities share responsibility?

  • Study beefs up support for brain cells that control protein hunger nerve-cell-2213009_1280

    Have you ever found yourself craving a steak or a burger? The brain controls our feelings of hunger and also determines the types of nutrients we should be seeking out. Not much is understood about the brain’s regulation of nutrient-specific hunger, but in a new study published in Science, researchers identified the brain cells in fruit flies that regulate protein hunger and were able to control those cells, affecting what the animals ate. The study, was funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.